Table. Demographic and Clinical Characteristics of Patients With Melanoma and Controlsa.
| Characteristic | Controls (n = 49) | All patients with melanoma (n = 179) | P valueb | Patients with early-stage melanoma (n = 38) | Patients with late-stage melanoma (n = 141) | P valuec |
|---|---|---|---|---|---|---|
| Demographic | ||||||
| Age, median (range), y | 40 (24-66) | 64 (21-90) | <.001 | 65 (23-82) | 64 (21-90) | .96 |
| Sex | ||||||
| Women | 34 (69.4) | 68 (38.0) | <.001 | 17 (44.7) | 51 (36.2) | .35 |
| Men | 15 (30.6) | 111 (62.0) | 21 (55.3) | 90 (63.8) | ||
| BMI, median (range) | 25.1 (16.2-45.4) | 28.6 (19.3-50.2)d | .002 | 28.0 (19.3-38.8) | 28.8 (19.6-50.2)d | .20 |
| Race and ethnicity | ||||||
| Asian | 7 (14.3) | 2 (1.1) | <.001 | 0 | 2 (1.4) | .99 |
| White | 27 (55.1) | 177 (98.9) | 38 (100) | 139 (98.6) | ||
| Missing | 15 (30.6) | 0 | 0 | 0 | ||
| Clinical | ||||||
| Medications used within 30 d | ||||||
| Antibiotics | 0 | 65 (36.3) | <.001 | 4 (10.5) | 61 (43.3) | <.001 |
| PPIs or H2-receptor antagonists | 3 (6.1) | 43 (24.0) | .01 | 6 (15.8) | 37 (26.2) | .21 |
| Metformin | 1 (2.0) | 15 (8.4) | .20 | 2 (5.3) | 13 (9.2) | .74 |
| Statins | 4 (8.2) | 58 (32.4) | <.001 | 12 (31.6) | 46 (32.6) | .99 |
| Corticosteroids | 0 | 12 (6.7) | .07 | 0 | 12 (8.5) | .07 |
| Stage | ||||||
| In situ | NA | 7 (3.9) | NA | 7 (18.4) | NA | <.001 |
| I | NA | 22 (12.3) | 22 (57.9) | NA | ||
| II | NA | 9 (5.0) | 9 (23.7) | NA | ||
| III | NA | 66 (36.9) | NA | 66 (46.8) | ||
| IV | NA | 75 (41.9) | NA | 75 (53.2) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); H2, histamine; NA, not applicable; PPI, proton pump inhibitor.
a
Unless otherwise indicated, data are expressed as No. (%) of participants.
b
Compares characteristics between controls and all patients with melanoma.
c
Compares characteristics between patients with early-stage and late-stage melanoma.
d
Missing BMI value for 1 patient with late-stage melanoma.